- Record: found
- Abstract: not found
- Article: not found
Abstract PD11-09: PD11-09 Datopotamab Deruxtecan (Dato-DXd)+ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.